Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	10/553,028	10/11/05	Belmares *et al.*	514	018	10/11/05
	A2	2002/0110841	08/15/02	Kufe	435	7.23	12/26/01
	A3	2003/0148969	08/07/03	Dobie *et al.*	514	44	12/20/01
	A4	2004/0018181	01/29/04	Kufe *et al.*	424	93.21	05/29/03
	A5	2004/0166543	08/26/04	Kufe	435	7.23	12/11/03
	A6	2004/0209832	10/21/04	McSwiggen	514	44	09/23/03
	A7	2005/0042209	02/24/05	Kufe *et al.*	424	93.21	02/13/04
	A8	2005/0053606	03/10/05	Kufe *et al.*	424	155.1	09/11/01
	A9	5,506,343	04/09/96	Kufe	530	387.7	10/25/94
	A10	5,530,101	06/25/96	Queen *et al.*	530	387.3	12/19/90
	A11	5,612,895	03/18/97	Balaji *et al.*	702	19	04/21/95
	A12	5,766,833	06/16/98	Balance *et al.*	435	69.7	11/17/93
	A13	5,776,427	07/07/98	Thorpe *et al.*	424	1.49	06/01/95
	A14	5,801,154	09/01/98	Baracchini *et al.*	514	44	04/08/97
	A15	5,861,381	01/19/99	Chambon *et al.*	514	44	06/07/95
	A16	5,998,148	12/07/99	Bennett *et al.*	435	6	04/08/99
	A17	6,020,363	02/01/00	Hirano *et al.*	514	456	12/17/98
	A18	6,054,438	04/25/00	Taylor-Papadimitiou *et al.*	514	44	06/01/95
	A19	6,074,841	06/13/00	Gearing *et al.*	435	69.1	11/19/96
	A20	6,222,020	04/24/01	Taylor-Papadimitriou *et al.*	530	395	06/01/95
	A21	6,589,921	07/08/03	Herrmann *et al.*	514	456	02/27/01
	A22	6,716,627	04/06/04	Dobie	435	375	12/20/01

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A23	60/308,307	07/27/01	Kufe			07/27/01
	A24	60/502,111	09/11/03	Jecminek *et al.*			09/11/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	EP 1103623	07/01/98	Europe	English
	B2	WO 00/25827	05/11/00	WIPO	English
	B3	WO 00/34468	06/15/00	WIPO	English
	B4	WO 00/77031	12/21/00	WIPO	English
	B5	WO 01/12217	02/22/01	WIPO	English
	B6	WO 01/18035	03/15/01	WIPO	English
	B7	WO 01/57068	08/09/01	WIPO	English
	B8	WO 02/058450	08/01/02	WIPO	English
	B9	WO 02/22685	03/21/02	WIPO	English
	B10	WO 02/31512	04/18/02	WIPO	English
	B11	WO 03/014303	02/20/03	WIPO	English
	B12	WO 03/088995	10/30/03	WIPO	English
	B13	WO 2004/044160	05/27/04	WIPO	English
	B14	WO 2004/092339	10/28/04	WIPO	English
	B15	WO 93/20841	10/28/93	WIPO	English
	B16	WO 96/03502	02/08/96	WIPO	English

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," *Science,* 281:1322-1326, 1998.
	C2	Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" *Molecular Medicine Today,* 6:72-81, 2000.
	C3	Akagi *et al.*, "CA19-9 epitope a possible marker for MUC-1/Y protein," *Int. J. Oncol.,* 18:1085-1091, 2001.
	C4	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," *Curr. Opin. Cell Biol.,* 11:255-260, 1999.
	C5	Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," *Science,* 281:1305-1308, 1998.
	C6	Ashkenazi *et al.*, "Safety and antitumor activity of recombinant soluble Apo2 ligand," *J. Clin. Invest.,* 104:155-162, 1999.
	C7	Backstom *et al.*, "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," *Biochemical Journal,* 376:677-686, 2003.
	C8	Banerjee, "Omega amino acids in peptide design: incorporation into helices ," *Biopolymers,* 39:769-77, 1996.
	C9	Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," *Hum. Pathol.,* 16:225-7, 1985.
	C10	Barry *et al.*, "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," *Biochemical Pharmacology,* 40:2353-2362, 1990.
	C11	Baruch *et al.*, "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," *Int. J. Cancer,* 71:741-749, 1997.
	C12	Baruch *et al.*, "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," *Cancer Res.,* 59:1552-1561, 1999.
	C13	Batra *et al.*, "Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes," *J. Cell Science,* 100:841-849, 1991.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Bellgrau *et al.*, "A role for CD95 ligand in preventing graft rejection," *Nature,* 377:630-632, 1995.
	C15	Berger *et al.*, "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," *American Journal of Respiratory Cell and Molecular Biology,* 20:500-510, 1999.
	C16	Bergeron *et al.*, "MAUB is a new mucin antigen associated with bladder cancer," *J. Biol. Chem.,* 271:6933-6940, 1996.
	C17	Beusen *et al.*, "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," *Biopolymers,* 36:181-200, 1995.
	C18	Bird *et al.*, "Single-chain antigen-binding proteins," *Science,* 242:423-6, 1988.
	C19	Bitko *et al.*, "Inhibition of respiratory viruses by nasally administered siRNA," *Nature Med.,* 11:50-55, 2005.
	C20	Bodmer *et al.*, "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," *J. Biol. Chem.,* 275:20632-20637, 2000.
	C21	Boldin *et al.*, "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," *Cell,* 85:803-815, 1996
	C22	Brossart *et al.*, "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," *Blood,* 93:4309-4317, 1999.
	C23	Brunner *et al.*, "*pangolin*encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in *Drosophila*," *Nature,* 385:829-33, 1997.
	C24	Bumcrot *et al.*, "RNAi therapeutics: a potential new class of pharmaceutical drugs," *Nature Chemical Biology,* 2:711-719, 2006.
	C25	Bunz, "Cell death and cancer therapy," *Curr. Opin. Pharmacol.,* 1:337-341, 2001.
	C26	Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," *J. Biol. Chem.,* 276:37879-37886, 2001.
	C27	Busfield *et al.*, "Characterization of a neuregulin-related gene, *Don-1*, that is highly expressed in restricted regions of the cerebellum and hippocampus," *Mol. Cell. Biol.,* 17:4007-4014, 1997.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Chang *et al.*, "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," *Nature,* 387:509-512, 1997.
	C29	Chaudhary *et al.*, "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," *Proc. Natl. Acad. Sci. U.S.A.*, 87:1066-70, 1990.
	C30	Ciborowski *et al.*, "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," *Tumor Biology*, 19:147-151, 1998.
	C31	Console *et al.*, "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," *J. Biol. Chem.*, 278 :35109-14, 2003.
	C32	Creagan *et al.*, "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," *J. Clin. Oncol.,* 17:1884-1890, 1999.
	C33	Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," *Mol. Cell. Biol.*, 19:3614-23, 1999.
	C34	Datta *et al.*, "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," *Cell Growth Differ,* 6:363-370, 1995.
	C35	Dawson *et al.*, "Synthesis of proteins by native chemical ligation ," *Science*, 266:776-779, 1994.
	C36	Deng *et al.*, "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," *Genes Dev.,* 16:33-45, 2002.
	C37	Derossi *et al.*, "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," *J Biol. Chem.*, 271:18188-93, 1996.
	C38	Derossi *et al.*, "The third helix of the Antennapedia homeodomain translocates through biological membranes," *J Biol. Chem.*, 269:10444-50, 1994.
	C39	Deveraux and Reed, "IAP family proteins--suppressors of apoptosis," *Genes Dev.*, 13:239-52, 1999.
	C40	Dillman, "Antibodies as cytotoxic therapy," *J. Clin. Oncology,* 12:1497-1515, 1994.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Dorn *et al.*, "Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2," *Anticancer Research*, 24:821-826, 2004.
	C42	Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," *Cell*, 85:1067-76, 1996.
	C43	Drucker *et al.*, "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," *Anticancer Research*, 23:1549-1554, 2003.
	C44	Du *et al.*, "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," *Cell*, 102:33-42, 2000.
	C45	Dykxhoorn *et al.*, "The silent treatment: siRNAs as small molecule drugs," *Gene Therapy*, 13:541-552, 2006.
	C46	Elbashir *et al.*, "Analysis of gene function in somatic mammalian cells using small interfering RNAs," *Methods*, 26:199-213, 2002.
	C47	Elbashir *et al.*, "RNA interference is mediated by 21-and 22-nucleotide RNAs," *Genes and Development*, 15:188-200, 2001.
	C48	Elliot and O'Hare, "Intercellular trafficking and protein delivery by a herpesvirus structural protein," *Cell*, 88:223-33, 1997.
	C49	Elmquist *et al.*, "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," *Exp. Cell Res.*, 269:237-44, 2001.
	C50	Emoto *et al.*, "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," *EMBO J.*, 14:6148-6156, 1995.
	C51	Faivre *et al.*, "Supraadditive effect of 2',2'difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines," *Cancer Chemother. Pharmacol.*, 44:117-123, 1999.
	C52	Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxathiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," *J. Amer. Chem. Soc.*, 108:181-2, 1986.
	C53	Finn *et al.*, "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," *Immunol. Rev.*, 145:61-89, 1995.
	C54	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," *Cell*, 55:1189-93, 1989.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," *J. Exp. Med.*, 190:891-893, 1999.
	C56	Futaki *et al.*, "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," *J. Biol. Chem.*, 276 :5836-40, 2001.
	C57	Geisbert *et al.*, "Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge is Conferred by RNA Interference," *J. Infectious Diseases*, 193:1650-1657, 2006.
	C58	Gendler *et al.*, "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," *J. Biol. Chem.*, 263:12820-12823, 1988.
	C59	Gendler *et al.*, "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," *J. Biol. Chem.*, 265:15286-15293, 1990.
	C60	Gopalakrishnan *et al.*, "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," *J. Biomol. Screen*, 7:317-23, 2002.
	C61	Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein ," *Cell*, 55:1179-88, 1989.
	C62	Griffith *et al.*, "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," *Immunity*, 5:7-16, 1996.
	C63	Gross *et al.*, "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," *J. Biol. Chem.*, 274:1156-1163, 1999.
	C64	Grzelinski *et al.*, "RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," *Human Gene Therapy*, 17:751-766, 2006.
	C65	Haim *et al.*, "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," *Am. J. Clin. Oncol.*, 22:47-50, 1999.
	C66	Hammond *et al.*, "Post-transcriptional gene silencing by double-stranded RNA," *Nature Genetics*, 2:110-119, 2001.
	C67	Hanson *et al.*, "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," *Breast Cancer Research and Treatment*, 67:215-222, 2001.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Harborth *et al.*, "Identification of essential genes in cultured mammalian cells using small interfering RNAs," *J. Cell Science,* 114:4557-4565, 2001.
	C69	Harrison, "Peptide-surface association: the case of PDZ and PTB domains," *Cell*, 86:341-343, 1996.
	C70	Hartman *et al.*, "MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer," *Int. J. Cancer,* 82:256-267, 1999.
	C71	Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," *Blood,* 98:2603-2614, 2001.
	C72	Higashiyama *et al.*, "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," *J. Biochem.*, 122:675-680, 1997.
	C73	Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy," *J. Pept. Res.*, 50:421-35, 1997.
	C74	Hird *et al.*, "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," *Br. J. Cancer,* 68:403-406, 1993.
	C75	Hruby et al., "Design of peptides, proteins, and peptidomimetics in chi space," *Biopolymers*, 43:219-66, 1997.
	C76	Hunt and Evans, "Till Death Us Do Part," *Science,* 293:1784-1785, 2001.
	C77	Huston *et al.*, "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," *Proc. Natl. Acad. Sci U.S.A.*, 85:5879-83, 1988.
	C78	Hymowitz *et al.*, "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," *Mol. Cell.*, 4:563-571, 1999.
	C79	Ikeda *et al.*, "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid," *Molecular Cancer Therapeutics,* 3:39-45, 2004.
	C80	Irmler *et al.*, "Inhibition of death receptor signals by cellular FLIP," *Nature,* 388:190-195, 1997.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Itzkowitz *et al.*, "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," *Cancer*, 66:1960-6, 1990.
	C82	Jaattela *et al.*, "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," *Oncogene*, 10:2297-2305, 1995.
	C83	Jawhari *et al.*, "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," *J. Pathol.* 189:180-5, 1999.
	C84	Jen *et al.*, "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," *Stem Cells*, 18:307-319, 2000.
	C85	Jin *et al.*, "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," *Genes Dev.*, 17:359-67, 2003.
	C86	Kahn *et al.*, "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," *J. Amer. Chem. Soc.*, 110:1638-9, 1988.
	C87	Kahn, "The design and synthesis of mimetics of peptide beta-turns," *J. Molec. Recognition*, 1:75-9, 1988.
	C88	Kalofonos *et al.*, "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," *Cr. J. Cancer*, 59:939-942, 1989.
	C89	Kalofonos *et al.*, "Radioimmunoschintigraphy in patients with ovarian cancer," *Acta Oncologica*, 38:629-634, 1999.
	C90	Karvinen *et al.*, "Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3," *J. Biomol. Screen.*, 7:223-31, 2002.
	C91	Kataoka *et al.*, "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," *J. Immunol.*, 161:3936-3942, 1998.
	C92	Kayagaki *et al.*, "Metalloproteinase-mediated release of human Fas ligand," *J. Exp. Med.*, 182:1777-1783, 1995.
	C93	Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diaza-cyclodeca-2,7-dione the dilactam of L-alph,gamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," *Tet. Lett.*, 29:5057-60, 1988.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C94	Kennerdell *et al.*, "Heritable gene silencing in *Drosophila* using double-stranded RNA," *Nature Biotechnology,* 17:896-898, 2000.
	C95	Kharbanda *et al.*, "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2," *Cancer Res.,* 56:3617-3621, 1996.
	C96	Kim *et al.*, "Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," *Molecular Therapy*, 14:343-350, 2006.
	C97	Kischkel *et al.*, "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor," *EMBO J.,* 14:5579-5588, 1995.
	C98	Kluck *et al.*, "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," *Science,* 275:1132-1136, 1997.
	C99	Kondo *et al.*, "Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines," *Cancer Research,* 58:2014-2019, 1998.
	C100	Kroemer and Reed, "Mitochondrial control of cell death," *Nat. Med.,* 6:513-519, 2000.
	C101	Kufe *et al.*, "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," *Hybridoma,* 3:223-232, 1984.
	C102	Kumar *et al.*, "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571," *Mol. Pharmacol.,* 63:276-282, 2003.
	C103	Kuppuswamy *et al.*, "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," *Nucl. Acids Res.*, 17:3551-61, 1989.
	C104	LaVallee *et al.*, "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," *Cancer Research,* 63:468-475, 2003.
	C105	LeBlanc *et al.*, "Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," *Nat. Med.,* 8:274-281, 2002.
	C106	Lewis *et al.*, "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," *Nature Genetics,* 32:107-108, 2002.
	C107	Li and Kufe, "The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120^{ctn}," *Biochem. Biophys. Res. Commun.,* 281:440-443, 2001.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C108	Li *et al.*, "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," *Cell,* 94:491-501, 1998.
	C109	Li *et al.*, "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," *Cell,* 91:479-489, 1997.
	C110	Li *et al.*, "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," *Cancer Biol. Ther.,* 2:187-193, 2003.
	C111	Li *et al.*, "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," *Mol. Cancer Res.,* 1:765-775, 2003.
	C112	Li *et al.*, "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," *Oncogene,* 22:6107-6110, 2003.
	C113	Li *et al.*, "Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β -catenin," *Mol. Cell. Biol.,* 18:7216-7224, 1998.
	C114	Li *et al.*, "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin," *J. Biol. Chem.,* 276:6061-6064, 2001.
	C115	Li *et al.*, "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β-catenin," *JBC Papers in Press,* manuscript C100359200, August 1, 2001.
	C116	Li *et al.*, "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," *J. Biol. Chem.*, 276:35236-42, 2001.
	C117	Li *et al.*, "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," *Nature Med.*, 11:944-951, 2005.
	C118	Ligtenberg *et al.*, "Cell associated episialin is a complex containing two proteins derived from a common precurso," *J. Biol. Chem.,* 267:6171-6177, 1992.
	C119	Ligtenberg *et al.*, "Suppression of Cellular Aggregation by High Levels of Episialin," *Cancer Res.,* 52:2318-2324, 1992.
	C120	Lin et al., "Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," *J. Biol. Chem.*, 270:14255-8, 1995.
	C121	Liu *et al.*, "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," *Proc. Natl Acad. Sci. U.S.A.*, 93 :11819-24, 1996.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C122	Liu *et al.*, "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cyochrome c," *Cell,* 86:147-157, 1996.
	C123	Luo *et al.*, "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," *Molecular Pain,* 1:29, 2005.
	C124	Luo *et al.*, "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," *Cell,* 94:481-490, 1998.
	C125	Makimura *et al.*, "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," *BMC Neuroscience*, 3:18, 2002.
	C126	Maraveyas *et al.*, "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," *Cancer,* 73:1067-1075, 1994.
	C127	Maraveyas *et al.*, "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," *Cancer Research,* 55:1060-1069, 1995.
	C128	Mariani *et al.*, "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," *Eur. J. Immunol.*, 25:2303-2307, 1995.
	C129	Marsters *et al.*, "A novel receptor for Apo2L/TRAIL contains a truncated death domain," *Curr. Biol.,* 7:1003-1006, 1997.
	C130	Martinez *et al.*, "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," *Cell,* 110:563-574, 2002.
	C131	Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," *Cell Death Diff.*, 9:699-701, 2002.
	C132	McGuckin *et al.*, "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," *Human Pathology,* 26:432-439, 1995.
	C133	Mi *et al.*, "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," *Mol. Ther.*, 2:339-47, 2000.
	C134	Milik *et al.*, "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," *J. Clin. Invest.,* 99:1082-1091, 1997.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C135	Minakuchi *et al.*, "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," *Nucleic Acids Research*, 32:e109, 2004.
	C136	Molenaar *et al.*, XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos," *Cell*, 86:391-9, 1996.
	C137	Morris *et al.*, "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," *Nucleic Acid Res.*, 25:2730-6, 1997.
	C138	Muzio *et al.*, "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," *Cell*, 85:817-827, 1996.
	C139	Nagai and Sato, "Synthesis of a bicylic dipeptide with the shape of beta-turn central part," *Tet. Lett.*, 26:647-50, 1985.
	C140	Nagata, "Apoptosis by Death Factor," *Cell*, 88:355-365, 1997.
	C141	Nakamura *et al.*, "RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis," *Molecular Vision*, 10:703-711, 2004.
	C142	Nakashima et al., "Inhibition of angiogenesis by a new isocoumarin, NM-3," *J. Antibiotics*, 52:426-428, 1999.
	C143	Nicholson *et al.*, "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," *Oncology Reports* 5:223-226, 1998.
	C144	Niethammer *et al.*, "CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," *Neuron*, 20:693-707, 1989.
	C145	Niu *et al.*, "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," *Int. J. Gynecol. Cancer*, 16:743-751, 2006.
	C146	Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," *Cell Mol. Life Sci.*, 523-37, 1999.
	C147	Obermair *et al.*, "Expression of MUC1 splice variants in benign and malignant ovarian tumours," *Int. J. Cancer*, 100:166-171, 2002.
	C148	Oehlke *et al.*, "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," *Biochim. Biophys. Acta.*, 1414: 127-39, 1998.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C149	Okazaki *et al.*, "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," *J. Clin. Gastroenterol.*, 27(suppl. 1):S91-S92, 1998.
	C150	Opalinska *et al.*, "Nucleic-acid therapeutics: basic principles and recent applications," *Nature Reviews Drug Discovery,* 1:503-514, 2002.
	C151	Padrón *et al.*, "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," *Anti-Cancer Drugs,* 10:445-452, 1999.
	C152	Palliser *et al.*, "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," *Nature*, 439:89-94, 2006.
	C153	Pan *et al.*, "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," *Science,* 277:815-818, 1997.
	C154	Pan *et al.*, "The Receptor for the Cytotoxic Ligand TRAIL," *Science,* 276:111-113, 1997.
	C155	Parrish *et al.*, "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," *Molecular Cell,* 8:1077-1087, 2000.
	C156	Paszkiewicz-Gadek *et al.*, "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," *Gynecol. Endocrinol.*, 17:37-44, 2003.
	C157	Pavlovic *et al.*, "Targeting of non-small cell lung cancer using HMFG1-^{99m}TC monoclonal antibodies," *Med Pregl.*, 46 Suppl 1:26-28, 1993
	C158	Perey *et al.*, "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," *Cancer Research,* 52:2563-2568, 1992.
	C159	Perez *et al.*, "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," *J. Cell. Sci.*, 102:717-22, 1992.
	C160	Pescarolo *et al.*, "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," *FASEB J.*, 15:31-3, 2001.
	C161	Pitti *et al.*, "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," *J. Biol. Chem.*, 271:12687-12690, 1996.
	C162	Pooga *et al.*, "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo," *Nature Biotech.*, 16 :857-61, 1998.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: **Michael P. BELMARES *et al.***	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C163	Porowska *et al.*, "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," *Neoplasma*, 49:104-109, 2002.
	C164	Price *et al.*, "Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, *Tumor Biol.*, 19:sup. 1:1-20, 1998.
	C165	Reddish *et al.*, "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," *Cancer Immunol. Immunother.*, 42:303-9, 1996.
	C166	Reich *et al.*, "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," *Molecular Vision*, 9:210-216, 2003.
	C167	Ren *et al.*, "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," *Cancer Cell*, 5:163-175, 2004.
	C168	Ren *et al.*, "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," *J. Biol. Chem.*, 277:17616-17622, 2002.
	C169	Reynolds *et al.*, "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," *Mol. Cell. Biol.*, 14:8333-42, 1994.
	C170	Reynolds *et al.*, "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," *Mol. Cell. Biol.*, 9:629-38, 1989.
	C171	Rondinone, "Therapeutic potential of rnai in metabolic diseases," *BioTechniques*, 40:S31-S36, 2006.
	C172	Rousselle *et al.*, "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," *Mol. Pharmacol.*, 57 :679-86, 2000.
	C173	Ruben *et al.*, "Structural and functional characterization of human immunodeficiency virus tat protein," *J. Virol.*, 63(1):1-8, 1989.
	C174	Sato *et al.*, "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," *Science*, 268:411-415, 1995.
	C175	Scaffidi *et al.*, "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," *J. Biol. Chem.*, 274:22532-22538, 1999.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C176	Schiffelers *et al.*, "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," *Nucleic Acids Research*, 32:e149, 2004.
	C177	Schneider *et al.*, "Mutagenesis and selection of PDZ domains that bind new protein targets," *Nat. Biotech.*, 17:170-5, 1998.
	C178	Schultz *et al.*, "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," *Nat. Struct. Biol.*, 5:19-24, 1998.
	C179	Schumacher *et al.*, "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," *Cancer Research*, 61:3712-3717, 2001.
	C180	Shen *et al.*, "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," *Gene Therapy*, 13:225-234, 2006.
	C181	Shimazui *et al.*, "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," *Cancer Res.*, 56:4154-8, 1996.
	C182	Siddiqui *et al.*, "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," *Proc. Natl. Acad. Sci. USA*, 85:2320-2323, 1988.
	C183	Smith and Waterman, "Comparison of Biosequences," *Adv. Appl. Math.*, 2:482-9, 1981.
	C184	Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolinon-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," *J. Amer. Chem. Soc.*, 114:10672-4, 1992.
	C185	Snyder *et al.*, "Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating peptide," *PLoS Biology*, 2:186-93, 2004.
	C186	Songyang *et al.*, "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," *Science*, 275:73-7, 1997.
	C187	Soomets *et al.*, "Deletion analogues of transportan," *Biochim. Biophys. Acta*, 1467:165-176, 2000.
	C188	Soutschek *et al.*, "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," *Nature* , 432:173-178, 2004.
	C189	Spatola, "A Peptide Backbone Modifications," In: Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, 7:267-357, Marcell Dekker, NY, 1983.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C190	Srinivasan *et al.*, "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," *J. Biol. Chem.*, 273:4523-4529, 1998.
	C191	Srinivasula *et al.*, "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," *Mol. Cell.*, 1:949-957, 1998.
	C192	Stennicke *et al.*, "Pro-caspase-3 is a major physiologic target of caspase-8," *J. Biol. Chem.*, 273:27084-27090, 1998.
	C193	Strous and Decker, "Mucin-Type Glycoproteins," *Crit. Rev. Biochem., Mol. Biol.*, 27:57-92, 1992.
	C194	Subbarao *et al.*, "pH-dependent bilayer destabilization by an amphipathic peptide," *Biochemistry*, 26:2964-2972, 1987.
	C195	Takei *et al.*, "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," *Cancer Research*, 64:3365-3370, 2004.
	C196	Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," *Annu. Rev. Biochem.*, 59:237-52, 1990.
	C197	Taylor *et al.*, "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," *Drug Discovery Today*, 4:562-567, 1999.
	C198	Thakker *et al.*, "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," *Molecular Psychiatry*, 10:782-789, 2005.
	C199	Timmer *et al.*, "Fas receptor-mediated apoptosis: a clinical application?" *J. Pathol.*, 196:125-134, 2002.
	C200	Tondini *et al.*, "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for *in Vitro* purging of human bone marrow," *Cancer Research*, 50:1170-1175, 1990.
	C201	Topp *et al.*, "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation buy may not mediated the graft versus myeloma effect," *Blood*, 100: page Abstract No. 5191, 2002.
	C202	Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," *Curr. Protein Pept. Sci.*, 4:133-40, 2003.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C203	Tseng *et al.*, "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," *Mol. Pharmacol.*, 62:864-72, 2002.
	C204	Urban-Klein *et al.*, "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo," *Gene Therapy*, 12:461-466, 2005.
	C205	van Hof *et al.*, "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," *Cancer Research*, 56:5179-5185, 1996.
	C206	Verhagen *et al.*, "Identifcation of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," *Cell*, 102:43-53, 2000.
	C207	Vermeer *et al.*, "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," *Nature*, 422:322-326, 2003.
	C208	Vives *et al.*, "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," *J. Biol. Chem.*, 272 :16010-7, 1997.
	C209	Walczak *et al.*, "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," *EMBO J.*, 16:5386-5397, 1997.
	C210	Walczak *et al.*, "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo," *Nat. Med.*, 5:157-163, 1999.
	C211	Walsh *et al.*, "Heterogeneity of MUC1 expression by human breast carcinoma cell lines *in vivo* and *in vitro*," *Breast Cancer Research and Treatment*, 58:255-266, 2000.
	C212	Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," *Oncogene*, 24:8628-8633, 2003.
	C213	Wei *et al.*, "MUC1 oncoprotein stabilizes and activates estrogen receptor α," *Molecular Cell*, 21:295-305, 2006.
	C214	Wender *et al.*, "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," *Proc. Natl. Acad. Sci., U.S.A.*, 97:13003-8, 2000.
	C215	Williams *et al.*, "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," *J. Biol. Chem.*, 272:22349-54, 1997.

65038205.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: ARBV:003US	Serial No.: 10/553,028
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Michael P. BELMARES *et al.*	
(Use several sheets if necessary)	Filing Date: April 26, 2007	Group: 1654

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1-2	*See Page 2*	*See Page 3-19*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C216	Wreschner *et al.*, "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: *Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment,* Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994.
	C217	Xia *et al.*, "siRNA-mediated gene silencing in vitro and invivo," *Nature Biotechnology,* 20:1006-1010, 2002.
	C218	Yamamoto *et al.*, "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," *J. Biol. Chem.*, 272:12492-4, 1997.
	C219	Yang *et al.*, "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," *Science,* 275:1129-1132, 1997.
	C220	Zimmerman *et al.*, "RNAi-mediated gene silencing in non-human primates," *Nature*, 441:111-114, 2006.
	C221	Zrihan-Licht *et al.*, "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," *Eur. J. Biochem.*, 224:787-795, 1994.
	C222	Zrihan-Licht *et al.*, "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules," *FEBS Let.*, 356:130-136, 1994.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.